Cannabinoid receptors, located throughout the body, are involved in a variety of physiological processes (including appetite, mood, etc.). A 2019 study shows that blocking CB1Rs (cannabinoid receptors that conserve energy) is an effective way to manage metabolic disorders, such as obesity and Type-2 Diabetes.
It was a privilege to meet with the editor of Wiley Publishing Company’s Alcohol and Drug Abuse Weekly, Dr Peter Grinspoon, and a select group of MA dispensary representatives this weekend, to discuss our shared goals & plan to support global access to education, of physicians, the #MedicalCommunity, the #CannabisIndustry, and the #CannabisCommunity.
Benjamin Caplan, MDDr Caplan & Dr Grinspoon meet with Wiley’s Alcohol and Drug Abuse Weekly
In a study that excluded cannabis users, researchers found that alcohol hangovers significantly impair both executive function (paying attention, regulating emotions, etc.) and prospective memory (remembering future plans).
Study finds that most young adult smokers engage in multiple other health risk behaviors. When placed in an intervention, participants were most ready to change their stress management and least ready to change their cannabis use.
Pharmaceutical Cannabis Derivatives Help Discover their Receptors and Functions for Autoimmune Illnesses
A recent study conducted by Michigan State University exposed the potential for cannabinoid receptor 2 (CB2) to target the treatment of inflammatory conditions. Elevated levels of plasmacytoid dendritic cells (pCD, a type of cell in the immune system) contribute to chronic inflammation in autoimmune diseases, such as Rheumatoid Arthritis. Researchers found that synthetic CB2 agonists reported comparable benefits to THC, but minimized the cerebral effects as the psychotropic activity is mediated by cannabinoid receptor 1 (CB1). This evidence demonstrates the potential benefits of CB2-targeted treatment for inflammatory conditions. Unfortunately, there are serious concerns about the misuse of some synthetic cannabinoids, so there is still a missing bridge, in products and public education, between these research products and potential therapeutic pharmaceuticals, down the road.
Preferences for Medical Marijuana over Prescription Medications Among Persons Living with Chronic Conditions: Alternative, Complementary, and Tapering Uses
In a survey of 30 patients using medical cannabis for a range of illnesses, including Rheumatoid Arthritis, cancer, Hepatitis C, PTSD, and more, patients reported an array of benefits from their cannabis use. Patients successfully used cannabis as an alternative to prescription medication, as a complementary agent with traditional prescription medicines, and to gradually help halt the use of some prescription medications. Benefits described by participants included the effects of cannabis lasting longer than that of opioids, lower risk of addiction, fewer side-effects. Patients also saw their sleep, anxiety, appetite, and adverse reactions improve with the use of medical cannabis. Larger, more controlled studies may suggest cannabis more affirmatively as an alternative or complementary therapy with prescription medications.
Overlaps in pharmacology for the treatment of chronic pain and mental health disorders
Select small trials have demonstrated cannabis to be more effective than other analgesics to treat chronic pain associated with certain conditions. However, the existing research lacks large-scale, controlled experiments relating medical cannabis use to pain management. Additionally, negative effects are documented with respect to cannabis use among adolescents and those suffering from compromised mental health. There is a need for further research on the topic.
Dentists’ concerns about the negative effects of cannabis on teeth are legitimate: dry mouth can lead to cavities. It is known that the terpene Delta-3-Carene can dry out bodily fluids (saliva), so avoiding strains w/ high levels can help. http://bit.ly/2KFpp0K
Benjamin Caplan, MDCannabis and Cavities, Delta-3-Carene